Osimertinib in Stage III EGFR-Mutated NSCLC — Game, Set, Match

Exactly 20 years ago, the precision-medicine revolution in lung cancer began with the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain,1,2 predicting dramatic patient benefit from EGFR tyrosine kinase inhibitors (TKIs). By 2024, routine testing for genomic alterations has expanded to nine…

​   The New England Journal of Medicine: Search Results in Pulmonary/Critical Care